The European healthcare private equity (PE) landscape is undergoing a structural reallocation of capital. Private equity sponsors, growth equity funds and institutional investors are shifting capital away from early-stage, speculative diagnostic tools and high-risk Software as a Medical Device (SaMD) platforms toward mission-critical operational workflow software. Historically, diagnostic artificial intelligence and novel MedTech tools commanded premium valuations based on t

The Finnish health technology and medical technology sector has, by the first quarter of 2026, successfully navigated a transformation from a fragmented landscape of high-potential startups into a unified, mature industrial powerhouse. This evolution is not merely a quantitative increase in export values or corporate valuations but represents a fundamental shift in the "industrial logic" of the ecosystem.

Nelson Advisors partner Lloyd Price co-authored the Oxford University Venture Capital Network: Insights into Digital Health Report with Ava Chan - DPhil candidate in Biology, Ellena O’Keeffe - MSc in Applied Cancer Science, Sili (Bobby) Qiu - DPhil candidate in Organic Chemistry, Adriana Mordente - DPhil candidate in Biology, Aneshka Moudry - MChem Chemistry.